New cocktail aims to wipe out CLL early
NCT ID NCT01723839
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested a combination of chemotherapy (FCR) plus the drug lenalidomide in 21 people with previously untreated chronic lymphocytic leukemia (CLL). The goal was to see if adding lenalidomide could help more patients achieve a complete response, meaning no signs of cancer remain. Participants received 4 to 6 cycles of the combo, followed by lenalidomide alone as maintenance. The study is now complete.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FCR chemotherapy (fludarabine, cyclophosphamide, rituximab) plus lenalidomide
What this could lead to
If successful, this combination could improve the chance of wiping out all signs of CLL after initial treatment, potentially leading to longer remission without needing ongoing therapy.
What could go wrong
This is a small, early-phase trial with only 21 people, so results may not apply to everyone. The treatment can cause serious side effects like low white blood cell counts (neutropenia), and lenalidomide may add extra risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
John Theurer Cancer Center at HackensackUMC
Hackensack, New Jersey, 07601, United States